MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 127.5 USD | -0.01% |
|
-2.01% | +16.96% |
| May. 02 | Merck: encouraging results in gastric cancer | CF |
| May. 01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
Presentation Operator MessageOperator (Operator)At this time, please welcome Merck's Executive...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
127.5
USD
Average target price
141.6
USD
Spread / Average Target
+11.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.96% | 323B | |
| +31.24% | 662B | |
| +21.96% | 546B | |
| -5.32% | 359B | |
| +4.75% | 289B | |
| +13.68% | 234B | |
| +3.81% | 198B | |
| -10.63% | 194B | |
| +3.86% | 167B | |
| -2.19% | 157B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc. - Shareholder/Analyst Call